Fast Company announced the winners of its prestigious Innovation by Design Awards, and we’re excited to share that two CannonDesign projects received kudos: Malcolm X College’s Health Sciences Campus was named a finalist in the Spaces, Places, and Cities category, and the Novartis-Penn Center for Advanced Cellular Therapies (CACT) was named an honorable mention in the Health category. All of the honorees are featured in the October issue of the print magazine, available at newsstands on September 19.
Now in its sixth year, the Innovation by Design Awards program honors the most innovative and disruptive design solutions created to resolve today’s most challenging business issues. Finalists were selected from a record number of more than 2,500 international submissions across 13 categories — ultimately recognizing 299 entrants — the most winners, finalists and honorable mentions in the history of the awards. See the full list of winners here.
Located in the near-west side of Chicago, Malcolm X College’s Health Sciences Campus is one of eight finalists in the Spaces, Places and Cities category. Recognizing a gap between the current market of qualified healthcare professionals and the projected 84,000 healthcare jobs set to come on-line in the Chicago region over the next decade, the campus helps City Colleges of Chicago connect its historically underserved student population with life-sustaining job opportunities. The building drastically shifts the dynamics of what people think about community college, introducing a first-class institution filled with simulation labs, a mock hospital, student union, library, day care center and more. Since opening in 2015, 92 percent of its nursing students have passed their licensure exams on their first try, and overall, the campus has doubled its graduation rate.
Located in Philadelphia, Novartis-Penn CACT received an honorable mention in the Health category; CannonDesign was the only architect recognized in the category. The CACT combines Penn Medicine’s intellectual resources with Novartis’ leadership in the pharmaceutical industry to find the most effective treatments for cancer. Specifically, the space houses Penn’s groundbreaking research using Chimeric Antigen Receptor (CAR) technology, which enables a patient’s own immune cells to be reprogrammed outside of their body and re-infused to “hunt” for and potentially destroy tumors. The strategic layout and organization of the CACT are ultimately reducing the time it takes to create the “hunter cells” for each patient by 50%. At the outset of this effort, it took an entire month to accomplish this for each patient.